BusinessAbeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive OfficerBy Nasdaq OMXApr 2, 2018, 12:15 PM UTC
BusinessAbeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business HighlightsBy Nasdaq OMXMar 16, 2018, 9:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 DiseaseBy Nasdaq OMXMar 15, 2018, 12:45 PM UTC
BusinessAbeona Therapeutics Announces Upcoming Conference ParticipationBy Nasdaq OMXFeb 21, 2018, 1:45 PM UTC
BusinessAbeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the MesaBy Nasdaq OMXOct 6, 2017, 12:25 PM UTC
BusinessAbeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, OhioBy Nasdaq OMXOct 4, 2017, 12:45 PM UTC
BusinessAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 30, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 30, 2017, 12:32 PM UTC
